What tacrolimus trough concentration should be targeted in pediatric patients with type 1 autoimmune hepatitis?

Target Tacrolimus Trough Levels in Pediatric Type 1 Autoimmune Hepatitis

Target tacrolimus trough levels of 0.6-1.0 ng/mL (or approximately 6 ng/mL based on more recent data) should be achieved in pediatric patients with type 1 autoimmune hepatitis when using tacrolimus as second-line therapy for refractory disease or intolerance to standard treatment.

Dosing and Monitoring Strategy

Initial Dosing

Start tacrolimus at 0.075 mg/kg daily (typical range 0.5-1 mg daily), adjusting according to tolerance to reach a maintenance level of 1 mg daily to 3 mg twice daily 1. The goal is to achieve the target trough concentration while minimizing toxicity.

Target Trough Concentrations

The evidence provides two slightly different target ranges:

• 0.6-1.0 ng/mL: This is the target range specified in the 2013 guideline for autoimmune hepatitis specifically 1
• Mean trough of 6 ng/mL: More recent data from the largest single-center experience showed that 12/13 patients with refractory AIH achieved normalization of liver tests at a mean trough level of 6 ng/mL 2

The practical recommendation is to target 5-7 ng/mL initially, which balances efficacy with safety, as this range has demonstrated excellent biochemical response rates in refractory AIH 2.

Clinical Context and Indications

When to Use Tacrolimus

Tacrolimus should be considered as second-line therapy in pediatric AIH patients who:

1. Fail to respond to standard therapy (prednisone/prednisolone with azathioprine)
2. Are intolerant to azathioprine (though mycophenolate mofetil may be preferred in this scenario)
3. Require high-dose, long-term steroids (>20 mg/day) despite optimization of conventional treatment 2

Efficacy Data in Children

The evidence for tacrolimus in pediatric AIH is promising but limited:

• Complete response rates of 65-70% in children receiving tacrolimus as second-line therapy 3
• 87.5% maintained biochemical remission in children intolerant to standard therapy 3
• 50% achieved complete response in non-responders to standard therapy (compared to 22.2% with mycophenolate mofetil, though not statistically significant) 3
• In systematic review/meta-analysis: 50% response rate at 6 months (though with wide confidence intervals due to small sample size) 4

Important Caveats and Monitoring

Toxicity Considerations

Monitor closely for neurotoxicity, nephrotoxicity, and infectious complications, as these are the primary concerns with calcineurin inhibitor therapy 1. The incidence of toxicity increases significantly at plasma concentrations >15 μg/L (though this data is from transplant literature) 5.

Comparison with Other Second-Line Agents

The choice between tacrolimus and other second-line agents should consider:

• Cyclosporine: Higher response rate (83% at 6 months) but also highest adverse event rate (64-78%) 4
• Mycophenolate mofetil: Lower response rate in refractory disease (22-36%) but better tolerated and more effective for azathioprine intolerance (58% response) 1, 3, 4
• Tacrolimus appears most effective for truly refractory disease rather than drug intolerance 3, 6

Practical Monitoring Schedule

1. Measure trough levels 12 hours post-dose (standard therapeutic drug monitoring practice)
2. Check levels frequently during dose titration (weekly initially)
3. Monitor liver biochemistry (AST, ALT, IgG) at baseline, 6 months, and 12 months
4. Assess for adverse effects including renal function, blood pressure, glucose, and neurological symptoms
5. Consider dose reduction of concomitant steroids once biochemical response is achieved 7

Limitations and Uncertainties

The evidence base for tacrolimus in pediatric AIH has significant limitations:

• No randomized controlled trials in children with AIH
• Small sample sizes in all published series (maximum 20 patients in any single study) 3, 4
• Short follow-up periods in most reports 2
• Target levels extrapolated primarily from adult data and transplant literature 1

Special Considerations for Children

Unlike adults, children require particular attention to growth and development when using immunosuppression. The goal is to minimize steroid exposure while achieving disease control. Tacrolimus allows for steroid dose reduction from 10 mg to 5 mg daily in responsive patients 7.

Consultation with a specialist center experienced in managing pediatric AIH is strongly recommended before initiating tacrolimus therapy 2, 8, 2.